Zepbound side effects: how common they are, what helps, when to call

Most people on tirzepatide get at least one stomach-related side effect, and those symptoms cluster around dose increases. In the pooled Zepbound trials, 56% of people at each dose had a gastrointestinal side effect, compared with 30% on placebo. The table below comes straight from the label, which combines two placebo-controlled weight-management trials (2,519 people on tirzepatide, 958 on placebo, up to 72 weeks).

How common are Zepbound side effects?

A few patterns are worth noticing. Nausea does not keep climbing with dose; 10 mg and 15 mg are about the same. Constipation runs the other way and is highest at 5 mg. Vomiting scales most cleanly, from 8% to 13%.

Severe stomach trouble is much less common than the headline numbers suggest. Severe gastrointestinal reactions affected 1.7% on 5 mg, 2.5% on 10 mg and 3.1% on 15 mg, against 1% on placebo. Overall, 4.8%, 6.3% and 6.7% of people stopped treatment because of a side effect, against 3.4% on placebo, and most of them did so in the first few months.

The Mounjaro label’s table from type 2 diabetes trials shows lower numbers for the same drug: nausea 12% to 18%, diarrhea 12% to 17%, vomiting 5% to 9%, constipation 6% to 7%. The drug is identical; the trial populations and background treatments were not. Sleep apnea trials reported side effects similar to the weight-management trials.

Mounjaro’s label adds some detail for specific groups. Decreased appetite ran 5% to 11%. In the heart outcomes trial, with 6,647 people on Mounjaro, the label singles out decreased appetite (17%), constipation (13%), vomiting (12%), abdominal pain (10%) and fatigue (10%). Children 10 and older had more vomiting, abdominal pain and low blood sugar than adults. During the 30-week placebo-controlled period, vomiting hit 16% on 5 mg and 12% on 10 mg against 3% on placebo, and abdominal pain 22% and 15% against 9%.

How long do Zepbound side effects last?

Most stomach symptoms show up around dose increases and settle with time, and constipation is the slow one. The Zepbound label states that the majority of nausea, vomiting and diarrhea events “occurred during dose escalation and decreased over time.” It gives no day-by-day timeline, so the figures below come from a clinician consensus on the GLP-1 class as a whole. Treat them as a general guide, since they were not measured on tirzepatide specifically.

Each step up the tirzepatide dosage ladder can bring a new round, which is why the label sets at least 4 weeks on each dose. A long gap can matter too. The label does not cover restarting, and the dosage chart explains what Lilly’s trials did after several missed doses.

Why the stomach takes the hit

Tirzepatide delays gastric emptying, so food stays in the stomach longer. The label says this delay is largest after the first dose and shrinks over time, which fits how symptoms usually behave. It also lowers calorie intake, probably by acting on appetite. The escalation schedule exists for this reason: the label says to follow it “to reduce the risk of gastrointestinal adverse reactions.”

What helps with Zepbound nausea and stomach symptoms?

Small changes to how you eat are the first step, according to clinical reviews. A 2025 Mayo Clinic Proceedings review says management should start with smaller, more frequent meals, adequate fluids, and avoiding high-fat or high-sugar foods. The table below draws on that review and on the multidisciplinary consensus cited above. Most of this advice rests on expert opinion, because few trials have tested these tips directly.

If diet changes are not enough, the same sources describe steps your prescriber can take:

• Stay longer on the current dose. The consensus describes extending a step by 2 to 4 weeks, and avoiding increases while symptoms persist. The label’s 4 weeks is a minimum.
• Drop back or pause. Going to a lower dose or temporarily holding treatment are both described. The Zepbound label says a lower maintenance dose can be considered if one is not tolerated.
• Settle at a lower maintenance dose. Zepbound’s maintenance options are 5, 10 or 15 mg, so not everyone goes to the top.
• Look for another cause. Symptoms that persist despite these steps should be evaluated, since the drug may not be the reason.

Injection site reactions, seen in 6% to 8%, are the other common complaint. Rotating sites is a label instruction, and where to inject Zepbound shows how.

Less common side effects people ask about

• Hair loss. The label ties it to weight reduction. It was reported by 7.1% of women and 0.5% of men on Zepbound, and no one on the drug quit because of it.
• Tiredness. Fatigue, weakness and malaise were counted together: 5% to 7% versus 3% on placebo.
• Dizziness or low blood pressure. Low blood pressure occurred in 1.6% versus 0.1% on placebo, more often in people taking blood pressure medicine (2.2%) and sometimes alongside stomach symptoms and dehydration.
• Skin sensations. Dysesthesia, meaning odd or uncomfortable skin feeling, affected 0.2% to 0.4% versus 0.1%.
• Taste and mouth. Altered taste was reported by 0.4%, and dry mouth or throat by 1% versus 0.1%.
• Heart rate. Average heart rate rose by 1 to 3 beats a minute, with no rise on placebo.
• Antibodies. People who developed antibodies to tirzepatide had more injection site reactions (11.3% versus 1%) and more allergic-type reactions (6.2% versus 3%).
• Blood tests. Pancreatic enzymes can rise without symptoms: amylase by 20% to 25% and lipase by 28% to 35% on average. The label says the meaning is unknown without other signs of pancreatitis.

The serious warnings

The Zepbound label (revised August 2026) lists these in Section 5. Each is uncommon, and each is the reason a specific symptom should not be waited out.

• Thyroid C-cell tumors (boxed warning). Seen in rats at clinically relevant exposures; unknown in humans. Contraindicated with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Report a neck lump, hoarseness, trouble swallowing or shortness of breath.
• Severe gastrointestinal reactions. The label says use “has been associated with gastrointestinal adverse reactions, sometimes severe,” and that Zepbound “is not recommended in patients with severe gastroparesis,” a condition where the stomach empties very slowly. Reports since approval include bowel obstruction, ileus (a stalled bowel) and severe constipation with fecal impaction.
• Acute kidney injury from dehydration. Vomiting and diarrhea can drain fluids fast. Most reported events followed stomach symptoms, and some cases needed dialysis. In the trials it was reported in 0.5% versus 0.2% on placebo.
• Acute gallbladder disease. Gallstones occurred in 1.1% versus 1% on placebo, and gallbladder inflammation in 0.7% versus 0.2%. The label links these events with weight reduction. Upper stomach pain, fever, yellow skin or eyes, or clay-colored stools are the signs.
• Acute pancreatitis. Confirmed cases were 0.2% in both arms of the weight trials. In the sleep apnea trials the rate was 0.84 per 100 patient-years on Zepbound and 0 on placebo. The label notes that severe forms, including fatal ones, have been seen with this drug class or Zepbound. Severe, persistent stomach pain that may spread to the back, with or without vomiting, is the symptom.
• Hypersensitivity reactions. Immediate reactions within a day occurred in 2.1% versus 0.4%; severe reactions in 0.1% versus none. Anaphylaxis and angioedema have been reported since approval. Most trial reactions were rash or itching.
• Hypoglycemia. In the trial of people with type 2 diabetes, blood glucose below 54 mg/dL occurred in 4.2% versus 1.3% on placebo, and in 10.3% of those also on a sulfonylurea. The label says the risk “may be lowered by a reduction in the dose of insulin or sulfonylurea,” which is a prescriber decision.
• Diabetic retinopathy complications. Fast improvement in blood sugar can temporarily worsen diabetic eye disease, so people with a history of retinopathy should be monitored.
• Pulmonary aspiration during anesthesia or deep sedation. Because the stomach empties slowly, food can remain in it during a procedure, even after fasting. The label says the data are too limited to give a fix, so every clinician involved needs to know you take tirzepatide.
• KwikPen sharing. A KwikPen should never be shared between people, even with a new needle, because of the risk of blood-borne infection.

One warning has gone the other way. When Zepbound was approved in November 2023, the FDA told clinicians to monitor for suicidal thoughts or behavior. The current label’s list of recent changes marks “Suicidal Behavior and Ideation” as removed in February 2026. A new or worsening mood change still deserves a call.

When to stop and call

Lilly’s patient safety summary sorts symptoms by urgency, and this table follows its wording. These are the manufacturer’s instructions, not this site’s.

Severe constipation belongs on that call list too, given the fecal impaction and bowel obstruction reports in the label. If you take too much, the summary says to call your provider, call Poison Help at 1-800-222-1222, or go to the nearest emergency room right away. Side effects can be reported to the FDA at 1-800-FDA-1088.

Medicines and situations that interact

• Birth control pills. Zepbound may make them less effective. The label advises switching to a non-oral method or adding a barrier method for 4 weeks after starting and for 4 weeks after each dose increase.
• Other oral medicines. Slower stomach emptying can affect how they are absorbed. The label asks for monitoring of drugs with a narrow safety margin, such as warfarin.
• Pregnancy. The label says Zepbound may cause fetal harm and should be stopped when pregnancy is recognized.
• Surgery. All your clinicians need to know before any planned procedure.
• Age 65 and older. The label reports no overall differences in safety or effectiveness in the weight trials, though few people over 75 were included.

A note on compounded tirzepatide

The percentages above come from trials of the FDA-approved product. Compounded tirzepatide was not in those trials. The FDA has logged more than 730 adverse event reports tied to it as of May 31, 2026, and says some reports may relate to patients prescribed doses beyond the label. The compounded tirzepatide guide covers the units math and what to check on the vial.

Who should not use tirzepatide at all

The label’s contraindications are a personal or family history of medullary thyroid carcinoma, Multiple Endocrine Neoplasia syndrome type 2, and a known serious allergic reaction to tirzepatide or any ingredient. It is not recommended with severe gastroparesis, and the Zepbound label advises against combining it with another tirzepatide product or a GLP-1 drug. The Medication Guide also asks you to tell your provider about past or current pancreas problems before starting. Those are prescriber decisions; this page only reports what the label says.